RecruitingNot ApplicableNCT06931002

A Rhinovirus Challenge Study to Investigate Exacerbations and Immune Responses in Bronchiectasis

Human Bronchiectasis Rhinovirus Challenge to Define Immunopathogenesis of Exacerbation


Sponsor

Imperial College London

Enrollment

54 participants

Start Date

Jul 24, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

The goal of this study is to determine if viral infection with the common cold leads to an exacerbation in participants with bronchiectasis. The investigators will compare the participants with bronchiectasis to a group of healthy participants. The main questions it aims to answer are: * Does viral infection with the common cold lead to an exacerbation in bronchiectasis? * Does the immune response differ to that of a healthy participant? Participants will attend for a screening visit to see if they are eligible. All participants who are eligible and have consented to take part will have baseline investigations done including blood tests and a bronchoscopy. They will be given a spray of a virus that causes the common cold into their nose. They will then be followed up over the next 6 weeks with some of the following procedures at each study visit; spirometry, nasosorption, nasal lavage, nasal brushing, blood test, sputum collection and a bronchoscopy. Participants will be asked to keep a daily record of their symptoms throughout the study.


Eligibility

Min Age: 18 YearsMax Age: 65 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a biological treatment called Rhinovirus A-16 Infection for people with bronchiectasis adult, bronchiectasis with chronic infection with pseudomonas aeruginosa, and other related conditions. The study is currently recruiting participants at 1 location.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BIOLOGICALRhinovirus A-16 Infection

All participants will be deliberately infected with Rhinovirus A-16


Locations(1)

St Mary's Hospital - Imperial Clinical Respiratory Research Unit (ICRRU)

London, United Kingdom

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06931002


Related Trials